Literature DB >> 21331690

Utility values in Japanese patients with exudative age-related macular degeneration.

Yasuo Yanagi1, Takashi Ueta, Ryo Obata, Aya Iriyama, Takashi Fukuda, Hideki Hashimoto.   

Abstract

PURPOSE: To investigate the utility values associated with visual loss due to age-related macular degeneration (AMD) in Japanese patients.
METHODS: Utility values in 48 Japanese patients with bilateral exudative AMD were measured using the time trade-off and standard gamble methods.
RESULTS: The time trade-off method utility values correlated with the best-corrected visual acuity (BCVA) in the better-seeing eye. The estimated utility values according to the BCVA in the better-seeing eye were 0.534 (BCVA, 0.01-0.15), 0.574 (0.2-0.3), 0.613 (0.4-0.6), and 0.653 (0.7-1.0). The utility values obtained by the standard gamble method were not significantly correlated with BCVA in the better-seeing eye.
CONCLUSIONS: The present results concur with those of previous studies showing that AMD causes a substantial decrease in patient utility values. The utility values obtained in the current study provide important information for use in cost-utility analysis of interventions for Japanese AMD patients. © Japanese Ophthalmological Society 2011.

Entities:  

Mesh：

Year:  2011        PMID： 21331690     DOI： 10.1007/s10384-010-0893-y

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN： 0021-5155            Impact factor:   2.447


  17 in total

1.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

Review 2.  Preference-based quality of life measures in people with visual impairment.

Authors:  Steven M Kymes; Bryan S Lee
Journal:  Optom Vis Sci       Date:  2007-08       Impact factor: 1.973

3.  A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Authors:  J Karnon; C Czoski-Murray; K Smith; C Brand; U Chakravarthy; S Davis; N Bansback; C Beverley; A Bird; S Harding; I Chisholm; Y C Yang
Journal:  Health Technol Assess       Date:  2008-06       Impact factor: 4.014

4.  A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Ophthalmology       Date:  2007-02-23       Impact factor: 12.079

5.  Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.

Authors:  N Bansback; S Davis; J Brazier
Journal:  Eye (Lond)       Date:  2006-11-10       Impact factor: 3.775

6.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

7.  Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration.

Authors:  Koko Saito; Teiko Yamamoto; Daijiro Tsuchiya; Ryo Kawasaki; Shion Haneda; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

8.  A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.

Authors:  Melissa M Brown; Gary C Brown; Heidi C Brown; Jonathan Peet
Journal:  Ophthalmology       Date:  2007-11-05       Impact factor: 12.079

9.  Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study.

Authors:  Ryo Kawasaki; Jie Jin Wang; Gui-jin Ji; Bronwen Taylor; Toshihide Oizumi; Makoto Daimon; Takeo Kato; Sumio Kawata; Takamasa Kayama; Yasuo Tano; Paul Mitchell; Hidetoshi Yamashita; Tien Yin Wong
Journal:  Ophthalmology       Date:  2008-01-25       Impact factor: 12.079

10.  Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version.

Authors:  Yoshimi Suzukamo; Tetsuro Oshika; Mitsuko Yuzawa; Yoshihiro Tokuda; Atsuo Tomidokoro; Kotaro Oki; Carol M Mangione; Joseph Green; Shunichi Fukuhara
Journal:  Health Qual Life Outcomes       Date:  2005-10-26       Impact factor: 3.186
View more
  5 in total

1.  Time Trade-off Utility Values in Noninfectious Uveitis.

Authors:  Katherine M Niemeyer; John A Gonzales; Thuy Doan; Erica N Browne; Maya M Rao; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2019-06-13       Impact factor: 5.258

2.  Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI.

Authors:  Hiroshi Tamura; Yoko Akune; Yoshimune Hiratsuka; Ryo Kawasaki; Ai Kido; Masahiro Miyake; Rei Goto; Masakazu Yamada
Journal:  Jpn J Ophthalmol       Date:  2022-01-07       Impact factor: 2.447

3.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

Review 4.  How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review.

Authors:  Deanna J Taylor; Angharad E Hobby; Alison M Binns; David P Crabb
Journal:  BMJ Open       Date:  2016-12-02       Impact factor: 2.692

Review 5.  Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review.

Authors:  Edith Poku; John Brazier; Jill Carlton; Alberto Ferreira
Journal:  BMC Ophthalmol       Date:  2013-12-04       Impact factor: 2.209
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.